CARDIFF ONCOLOGY, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
CARDIFF ONCOLOGY, INC. (CRDF) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$9.63 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-24
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$9.63M.
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$9.54M.
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$8.70M.
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$8.13M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$9.63M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$9.54M 10-K · filed 2026-02-24 |
| 2023-12-31 | -$8.70M 10-K · filed 2025-02-27 |
| 2022-12-31 | -$8.13M 10-K · filed 2024-02-29 |
| 2021-12-31 | -$5.94M 10-K · filed 2023-03-02 |
| 2020-12-31 | -$4.05M 10-K · filed 2022-02-24 |
| 2019-12-31 | -$3.45M 10-K · filed 2021-02-25 |
| 2018-12-31 | -$3.46M 10-K · filed 2020-02-27 |
| 2017-12-31 | -$8.59M 10-K · filed 2019-03-06 |
| 2016-12-31 | -$13.21M 10-K · filed 2018-02-26 |
| 2015-12-31 | -$9.34M 10-K · filed 2017-03-15 |
| 2014-12-31 | -$4.87M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |